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1. Introduction 
The C-25 hydroxylation of vitamin Da by liver 
microsomes [ 1 f and the subsequent C-l hydroxylation 
by the kidney mitochond~al2S-hydroxy~tam~ 
Ds-la-hydroxylase [2,3] result in the formation of the 
physiologically-active m tabolite of vitamin Ds iden- 
tified as 1,2Sdihydroxyvitamin Ds [ 1,2S-(OH),Ds] . 
This metabolite is regarded the hormonal form of the 
vitamin responsible for calcium and phosphate 
homeostasis inskeletal and soft tissue metabolism [4]. 
In studies of the 25hydroxyvitamin Ds-l- 
hydroxylase, the requirement for NADPH and the 
involvement ofcytochrome P4SO as a terminal oxidase 
in the production of 1 ,2S(OH)zD, were established 
[S-8]. The reduction of the cytochrome by NADPH 
is mediated by two intermediate oxidation-reduction 
components, namely, an iron-sulfur protein 
(ferredoxin) and a flavoprotein [8]. In this system, 
the renal ferredoxin, in a manner characteristic to
the hydroxylasesof anumber of steroidogenic tissues, 
mediates the transfer of electrons from a NADPH- 
specific flavoprotein dehydrogenase to a cytochrome 
P4SO. The purification and properties of the ferredoxin 
have been described [9]. 
Little biochemical information at the molecular 
level is availabie concerning quantitative modulations 
in the amount of the 1 -hydroxylase during skeletal 
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and soft tissue disorders. This communication attempts 
to provide preliminary answers in the form of quanti- 
tative anatomical distribution of the l-hydroxylase 
ferredoxin in the vitamin Ds-deficient chick as deter- 
mined by a double-~tibody radio~munoassay (RIA) 
of whole tissue extracts. The production of rabbit 
antichick ferredoxin and goat anti-rabbit r-globulin 
(IgG) antisera used in the development of the RIA are 
also described. 
2. Materials and methods 
2 .l . Purification of chick ferredoxin 
The kidney mitochondrial ferredoxin was purified 
to homogeneity as in [9]. 
2.2. Rabbit anti-ferredoxin antisera 
Antiserum to the ferredoxin was prepared by
vaccinating 6-8 lb New Zealand White rabbits with 
250 1.18 ferredoxin emulsified 1: 1 (v/v) in Freund’s 
complete adjuvant. The adjuvant was prepared by 
mixing SO ml Aquaphor (Biersdorf Inc., South 
Norwalk, CN), 100 ml Marco1 52 (Exxon Corp., 
Oak Brook, IL) and 200 mg M. butyricum (Difco 
Laboratories, Detroit, MI). Rabbits received 0.5 ml 
emulsified immunogen i  each rear foot pad and 
0.5 ml ~tra~apularly. After 10 days, the vaccina- 
tions were repeated as above. The rabbits were 
boosted by injecting into the marginal ear vein SO pg 
ferredoxin in 10 mM phosphate buffer (PH 7.4). The 
rabbits were bled 3-S days after booster vaccinations 
and sera were collected. Antibody titer was deter- 
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mined by the Ouchterlony double-diffusion procedure 
as detailed in [lo]. 
2.3. Goat an t&rabbit IgG antisera 
Antiserum to rabbit IgG y-globulins was prepared 
in 30-50 lb goats by two intrascapular injections of 
100 mg rabbit IgG purified and characterized as in 
[ 111. The goats were bled from the jugular veins 
1 week after the second injection. 
2 4. “‘Iodine-ferredoxin 
The ferredoxin in 10 mM Mops buffer (pH 7.4) 
was radiolabeled [9] using the iodine monochloride 
method [ 121 as modified ] 131. The radiolabeled 
protein was purified from the reaction mixture by 
passing the mixture through a Sephadex G-100 
column equilibrated with 10 mM Mops buffer (pH 7.4). 
Gamma radiation in column effluents was determined 
using a Beckman GM-100 counter equipped with a 
data computer. 
2 5. Microex traction of tissue 
Tissue, 100 mg in 0.4 ml 10 mM Mops buffer 
(pH 7.4) containing 0.1% Lubrol WX. as homogenized 
in a small (5 ml) ice-cold Potter-Elvehjem homogenizer 
fitted with a Teflon pestle. The homogenate was 
transferred into a Markson 5-ml RIA tube (Markson 
Science Inc., Del Mar, CA), frozen in dry ice, then 
immediately thawed in warm water. The freezing and 
thawing was repeated once again. The thawed prepara- 
tion was subjected to 4 X 15 s sonications at 4°C 
using the microtip assembly of Heat Systems model 
W-375 cell disruptor (Heat Systems Ultrasonics Inc., 
Plainview, NY). The sonicated preparation was 
centrifuged at 4°C for 30 min at 7000 rev./min. The 
supernatant was diluted 1 O-fold with 10 mM Mops 
buffer @H 7.4) and used in all subsequent assays. It is 
important to emphasize for reasons of potential clinical 
application that as little as 5 mg tissue could be 
processed as described here in a single RIA tube 
eliminating repetitive transfers and mechanical losses. 
The IO-fold dilution of final supernatant will not be * 
necessary under such circumstances. Instead, appro- 
priate aliquots of the supematant could be assayed 
directly. 
2.6. Radioimmunoassay 
To each RIA tube were added in the order given, 
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0.2 ml IgG-free rabbit serum albumin fraction V 
(10 mg/ml) in IO mM Mops (PH 7 -4) and an appro- 
priate aliquot of Mops buffer to give 0.3 ml total vol. 
when either standard ferredoxin solutions or tissue 
extracts were included. The tubes are vigorously 
vortexed to coat the inner surfaces. Appropriate 
aliquots of standard ferredoxin solution in 10 mM 
Mops buffer (5-100 ~.tl), or aliquots of 1 O-fold diluted 
tissue extracts (5-50 ~1) were then added to duplicate 
tubes. After the addition of a fixed amount of 
‘251-labeled ferredoxin to each tube (8000 cpm), the 
contents were mixed gently. Rabbit anti-ferredoxin 
antiserum, 0.2 ml diluted 25-fold with 10 mM Mops 
buffer @H 7.4), was then added to each tube. The 
mixtures were incubated with constant shaking for 
30 min in a water bath at 37°C. The tubes were 
removed from the bath and to each was added 0.2 ml 
goat anti-rabbit IgG anti-serum. After thorough 
mixing, the tubes were allowed to stand in the cold 
overnight then centrifuged at 4°C for 15 min at 
8000 rev./min. The supernatants were quantitatively 
transferred into new tubes and counted for gamma 
radiation. The pellets were also counted. Quantitative 
recovery of added radioactivity was obtained in the 
supernatant when all antisera were deleted from the 
assay incubations. A non-specific binding of 400 cpm 
was obtained when either antiserum was deleted. This 
number was used for calculating % binding of radio- 
labeled ferredoxin. 
3. Results 
The radioiodination of the ferredoxin gave spec. 
radioact. 0.07 @Zi/pg ferredoxin. Based on this activity, 
the fured amount of radioactivity added to each assay 
(8000 cpm) represents -50 ng ferredoxin total. Under 
these conditions as little as 25 ng ferredoxin could be 
detected in the aliquots of tissue extracts added to 
assay tubes. Considering mol. wt 53 000 for the 
ferredoxin [93, its detectable concentration in the 
assay mixture would be in the range 10-‘“-10-9 M. 
Figure 1 shows the results of Ouchterlony double- 
diffusion test for rabbit anti-ferredoxin antiserum 
titer. The single fusing precipitin arcs seen in pattern 
(b) are indicative of homogeneity of the antigen 
(kidney ferredoxin) and of the antibodies raised to 
this antigen. 
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Fig.1. Ouchterlony immunodiffusion pattern. The center 
well in pattern (b) contained 10 r.11 rabbit antiserum to the 
chick renal mitochondrial ferredoxin. The outer wells con- 
tamed renal ferredoxin beginning with upper left clockwise 
1.7 fig, 3.5 pg, 5.2 fig and 7 .O pg, respectively. The pattern 
in (a) is the same as the pattern in (b) but the well in the 
center of this pattern contained 10 ~1 rabbit pre-immune 
serum. The center well of pattern (cl contained 1 mg of 
immunoglobulin G protein obtained from fractionated goat 
anti-bovine adrenal ferredoxin antisera. The outer wells 
contained 8.7 ~g renal ferredoxin (upper left), 17.4 Mg renal 
ferredoxin (upper right), 3.6 pg adrenal ferredoxin (lower 
left), and 1.5 fig adrenal ferredoxin (lower right). 
Results of the quantitative precipitin test are 
shown in fig.2A. The formation of a complex between 
the rabbit y-globulins and the goat anti-rabbit 
y-globulin antiserum was maximum at 2.5fold dilution 
of rabbit serum when both reactants were present at 
a ratio of 1: 1. The formation of this complex was 
indicated as turbidity which was monitored by 
measuring A 750 in an AMINCO DW-2 UV/VIS spectro- 
photometer. This serum dilution and ratio were, there- 
fore, chosen for the development of the radioimmuno- 
assay. Figure 2B shows the standard curve obtained 
when the % bound 1251-labeled ferredoxin was plotted 
against known concentrations of competing unlabeled 
purified ferredoxin. Duplicate determinations are 
plotted for each concentration of ferredoxin. It can 
be seen that the usable sensitivity of the assay is as 
little as 25 ng (0.47 pmol) competing ligand. Half- 
&at MI-Rabbi1 QG Owntilativa Recyitin Tat 
@ 
Fig.2.4. Goat anti-rabbit IgG quantitative precipitin test. 
1.5 ml serially diluted normal rabbit serum was mixed with 
1.5 ml goat anti-rabbit IgG antiserum and incubated for 
30 min in a shaking water bath at 37°C. Turbidity measure- 
ments were made spectrophotometrically at 750 nm. 
maximal displacement of ‘*‘I-labeled ferredoxin is 
obtained at 300 ng nonradioactive ferredoxin in the 
0.7 ml assay volume. This corresponds to a concentra- 
tion of 8 nM. It is important to note that although 
IO-fold diluted extracts (0.01% in Lubrol) were 
routinely used in the assays to give a final Lubrol 
concentration of O.O007%with the use of the largest 
aliquot of extract (50 /_d), no measurable effect of 
this detergent on the binding properties of ferredoxin 
could be detected. In fact, as much as SO ~10.1% 
Fold Dilution d Rbbnt Swum 
Fig.ZB. Standard curve for the competitive radioimmuno- 
assay of renal ferredoxin. See text for details. 
185 
Volume 99, number 1 FEBS LETTERS March 1979 
D3- Doficimt 
I I I I 1 I I I I 1 
10 20 30 40 50 10 2D 30 40 50 
pl Diluted E:tract 
Fig.3. Comparative ferredoxin concentrations in liver and 
kidney of vitamin D,deficient versusvitamin D,-supplemented 
chicks as determined by radioimmunoassay. 
Lubrol(O.O07% final cont.) could be used without 
difficulty. The variations in the values obtained from 
duplicate assays or from different kidneys have con- 
sistently been within < 5%. 
Comparative f rredoxin concentrations in liver and 
kidney of vitamin Da-deficient versus vitamin 
Ds-supplemented chicks are shown in fig.3. First, the 
liver contains ferredoxin (at least a type recognized 
by the rabbit antibodies) at concentrations which, 
probably, are higher than that found in kidney. The 
presence of ferredoxins in liver mitochondria has only 
recently been documented although their quantitation 
has not yet been reported (14-16). Second, liver and 
kidney concentrations of ferredoxin do not seem to 
be influenced by the vitamin D3 status of the birds. 
This finding is in agreement with the recent results of 
immunofluorescent studies which demonstrated 
comparable fluorescence intensities in specific parts 
along the nephron of vitamin Da-deficient and vitamin 
Da-sufficient kidneys (Ghazarian and Garancis, sub- 
Table 1 
Tissue distribution of chick ferredoxin 
Tissue Ferredoxin content 
D,deticient 
ccg/mg pmol/mg 
tissue tissue 
D,-supplemented 
pg/mg pmol/mg 
tissue tissue 
Liver 0.64 12.0 0.64 12.0 
Kidney 0.44 8.3 0.40 7.6 
Testes 0.29 5.4 _a _ 
Duodenum 0.22 4.2 - - 
Lung 0.14 2.7 - - 
Heart 0.09 1.7 - - 
Colon 0.09 1.7 - - 
Muscle 0.00 0.0 - - 
a Not determined 
mitted for publication). It is likely, therefore, that 
the concentration of the renal ferredoxin is not a 
major factor in the modulation of the lo-hydroxylase 
activity. 
Tissue distribution of ferredoxin in the chick is 
shown in table 1. The most significant concentrations 
are those of the liver, kidney, testes and duodenum. 
The concentrations found in lung, heart, colon and 
muscle are strikingly small. This distribution appears 
to be consistent with the known functional significance 
of these tissues in hydroxylating (a) cholecalciferols 
(17,18), (b) testicular androgenic hormones (19) and 
(c) bile acids (14). The presence of ferredoxin and 
cytochrome P-450 in kidneys, testes, liver and 
intestine, or the participation of these molecules in 
the above biochemical events are well documented 
(8, 19-21). 
4. Discussion 
Although the 25-hydroxyvitamin Ds-1 -hydroxylase 
appears to be exclusive to kidney tissue (16), it is 
possible for the ferredoxin component of this enzyme 
to be immunogenically similar but functionally dis- 
similar to ferredoxin-type proteins in other tissues. 
The immunogenic similarity of the beef adrenal and 
chick renal ferredoxins in spite of their distinctly 
different biofunctional roles is a clear example (fig.1 
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pattern c> (9,22). While the exact relationship of the 
renal la-hydroxylase ferredoxin to those of non-renal 
tissue is not known, reports of the occurrence of 
cytochrome P450 and hydroxylating reactions, 
probably requiring ferredoxins, in duodenum and 
other non-renal tissues (16-22) underscore the 
significance of iron-sulfur proteins. 
In the chick, as in man, the kidney progresses 
through 3 stages of development; pronephros, 
mesonephros and metanephros. The latter is the 
definitive kidney. However, unlike the mammalian 
kidney, the unambiguous disection of the amorphous 
chick kidney to distinct medullary and cortical 
regions is not possible. In our continuing RIA studies 
with disected beef and rabbit kidney medullary and 
cortical tissues, the association of the ferredoxin with 
the juxtaglomerular apparatus (JGA) was suggested 
(J.G.G., Garancis, submitted). The relevance of this is 
that the JGA plays an important role in autoregula- 
tion of renal blood flow and in glomerular filtration 
rate. This regulation is mediated through the elabora- 
tion of renin by the juxtaglomerular cells in the wall 
of the afferent arteriole proximal to the glomerulus. 
The JGA is in an ideal position to ‘monitor’ incoming 
circulation since this area of the kidney receives the 
greatest blood flow. Because 25-OH-D3 is converted 
in the kidney to the active hormone, 1 ,25-(OH)2Da, 
and the production of the hormone is rigorously 
controlled by circulating blood calcium and phos- 
phate levels, it would be reasonable to assume that 
the site of l-hydroxylation in the kidney is in a 
position well exposed to ample blood flow. Such a 
position, already assigned one endocrine function 
(renin production), could be the juxtaglomerular 
apparatus. 
Finally, while bioassays and receptor binding 
assays are available [23] for the assessment of 
1 -hydroxylase activity, their disadvantages are that 
only the product of the enzyme activity is the 
parameter measured and not the actual concentra- 
tion of enzyme molecules. On the other hand, RIA 
directly measures modulations in enzyme concentra- 
tion independent of activity. This property is of 
paramount importance in the potential application of 
the procedures we have described to the quantitative 
evaluation of pathochemical changes in skeletal and 
soft tissue disorders that may involve the 25-hydroxy- 
vitamin Ds-1 -hydroxylase. 
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